Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II)

苏格兰是开展这项研究的理想地点，因为每个人都有一个唯一的参考号。这使得很容易将不同的健康数据集联系在一起，并基于来自250个普通诊所和120万个人(占总人口的22%)的数据构建一个电子队列。如此庞大的队列提供了广泛的区域覆盖范围，并允许对5岁以下的儿童或65岁以上的成年人等亚群进行调查。这些数据已经被收集用于常规护理--关于全科医生会诊、处方、非工作时间会诊、急救和住院的使用情况的信息。它还包括实验室测试，以诊断一个人感染冠状病毒，特别是新冠肺炎。个人将接受常规血液测试，未使用的血液样本将被储存，并最终进行新冠肺炎抗体检测，以计算出在疫情期间接触过新冠肺炎的人群比例。我们还将对患者样本中的病毒基因组进行测序。对这些数据的分析是在安全的避风港使用匿名数据进行的，因此无法识别个人身份。将对这一队列进行跟踪，以监测新冠肺炎疫情的进展，并评估哪些干预措施对治疗和预防病毒有效。

Scotland is an ideal place to carry out this research as there is a unique reference number for every individual. This makes it easy to link together different health datasets and construct an electronic cohort based upon data from 250 general practices and 1.2m individuals (22% of the population). Such a large cohort, gives wide regional coverage and permits investigation of subgroups such as children aged under 5 or adults over 65.These data are already being collected for routine care - information on GP consultations, prescriptions, out of hours’ consultations, use of accident and emergency and hospital admissions. It also includes laboratory tests to diagnose a person with coronavirus and specifically COVID-19. Individuals will be having routine blood tests and a sample of unused blood will be stored and eventually tested for the presence of COVID-19 antibodies to work out the proportion of the population exposed during the epidemic. We will also sequence virus genomes from a sample of patients. The analysis of these data is carried out in a safe haven using anonymised data so that individuals cannot be identified.This cohort will be followed up to monitor the progress of the COVID-19 epidemic and to evaluate which interventions are effective for treating and preventing the virus.